Serum microRNAs in clear cell carcinoma of the ovary

• मुख्य लेखकों: Angel Chao (लेखक), Chyong-Huey Lai (लेखक), Hua-Chien Chen (लेखक), Chiao-Yun Lin (लेखक), Chia-Lung Tsai (लेखक), Yun-Hsin Tang (लेखक), Huei-Jean Huang (लेखक), Chen-Tao Lin (लेखक), Min-Yu Chen (लेखक), Kuang-Gen Huang (लेखक), Hung-Hsueh Chou (लेखक), Ting-Chang Chang (लेखक), Shu-Jen Chen (लेखक), Tzu-Hao Wang (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Elsevier, 2014-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.
• Notes: 1028-4559; 10.1016/j.tjog.2014.07.005
• Keywords: clear cell carcinoma; hsa-miR-130a; microRNA; ovarian cancer; Gynecology and obstetrics; RG1-991
• Source: Taiwanese Journal of Obstetrics & Gynecology, Vol 53, Iss 4, Pp 536-541 (2014)

Objective: To identify candidate microRNAs (miRNAs) in the serum of patients with clear cell carcinomas in monitoring disease progression. Materials and methods: The sera of patients with diagnosed ovarian clear cell carcinoma were collected from 2009 to 2012. Real-time quantitative polymerase chain reaction (PCR) analysis for 270 miRNAs was performed. To offset the potential extraction bias, an equal amount of Caenorhabditis elegans cel-miR-238 was added to each serum specimen before miRNA isolation. miRNA expression was analyzed using the ΔCt method, with cel-miR-238 as controls. Results: Twenty-one patients with clear cell carcinoma were included. In the discovery phase on four pairs of pre- and postoperative sera, 18 differentially expressed miRNAs were selected from 270 miRNAs. In the validation phase on an independent set of 11 pairs of pre- and postoperative sera, 4 miRNAs (hsa-miR-130a, hsa-miR-138, hsa-miR-187, and hsa-miR-202) were confirmed to be higher in the preoperative sera. In the application phase, hsa-miR-130a remained consistent with the different time points in seven of the 10 patients during clinical follow-up periods. More importantly, in three patients, hsa-miR-130a levels were elevated in early disease recurrences before CA125 was found to be elevated. Conclusion: Hsa-miR-130a may be a useful serum biomarker for detecting recurrence of ovarian clear cell cancer, and warrants further studies.